The Journal of Rheumatology最新文献

Prevalence of Comorbidities and Poor Prognostic Factors Among Patients with Rheumatoid Arthritis in Bangladesh. 孟加拉国类风湿关节炎患者合并症和不良预后因素的患病率

The Journal of Rheumatology Pub Date : 2026-04-15 DOI: 10.3899/jrheum.2025-1272

Muhammad Shoaib Momen Majumder,Rijwan Bhuyian,Mohammad Jahid Hasan,Minhaj Rahim Choudhury,Syed Atiqul Haq,Michael T Nurmohamed

{"title":"Prevalence of Comorbidities and Poor Prognostic Factors Among Patients with Rheumatoid Arthritis in Bangladesh.","authors":"Muhammad Shoaib Momen Majumder,Rijwan Bhuyian,Mohammad Jahid Hasan,Minhaj Rahim Choudhury,Syed Atiqul Haq,Michael T Nurmohamed","doi":"10.3899/jrheum.2025-1272","DOIUrl":"https://doi.org/10.3899/jrheum.2025-1272","url":null,"abstract":"OBJECTIVEThis study aimed to assess the prevalence of comorbidities among Rheumatoid arthritis (RA) patients and identify factors associated with it.METHODSA cross-sectional study was conducted at 2-tertiary care hospitals among 653 patients with RA. Data on demographics, poor prognostic factors (high ESR, CRP, RF, anti-CCP antibody titres, and DAS28 > 5.1); and comorbidities were collected via a structured questionnaire and medical record review. Comorbidities were quantified via the Charlson Comorbidity Index (CCI). Logistic regressions were used to identify associated factors.RESULTSA total of 643 (98.5%) patients had ≥1 comorbidity. The most prevalent were dyslipidemia (75.8%), obesity (58.7%), hypertension (42.7%), type 2 diabetes (30.3%), and osteoporosis (15.6%). Age ≥ 45 years was independently associated with coronary artery disease (OR 9.71, 95% CI 1.91-178.00), osteoporosis (OR 19.60, 95% CI 5.96-121.00) and infectious diseases (OR 1.6, 95% CI 1.03- 2.54). Male sex was associated with increased cardiovascular risk (female OR 0.27, 95% CI 0.11-0.62), whereas female sex was associated with increased odds of osteoporosis (OR 3.55, 95% CI 1.71-8.37) and gastrointestinal disorders (OR 2.18, 95% CI 1.37-3.56). The use of tsDMARDs and bDMARDs increased the risk of infection (ORs of 14.80 and 4.11, respectively). High DAS28-CRP and ESR values were linked to gastrointestinal comorbidities. The CCI survival index was significantly lower in older patients (≥45 years) (mean 68.7, SD 26.7) than in younger patients (mean 93.3, SD 6.7, p < 0.001).CONCLUSIONPatients with RA in Bangladesh have high multimorbidity, particularly early CVD risk.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147684910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoantibodies and Relapse of Systemic Sclerosis After Autologous Hematopoietic Cell Transplantation. 自体造血细胞移植后自身抗体与系统性硬化症复发。

The Journal of Rheumatology Pub Date : 2026-04-15 DOI: 10.3899/jrheum.2025-0987

Daniel Levin,May Choi,Jean Kawasoe,Caylib Durand,Mohamad Osman,Hyein Kim,Iman Hemmati,Matthew Woo,Dorothy Li,Jonathan Howlett,Na Li,Faisal M Khan,Jan Storek

{"title":"Autoantibodies and Relapse of Systemic Sclerosis After Autologous Hematopoietic Cell Transplantation.","authors":"Daniel Levin,May Choi,Jean Kawasoe,Caylib Durand,Mohamad Osman,Hyein Kim,Iman Hemmati,Matthew Woo,Dorothy Li,Jonathan Howlett,Na Li,Faisal M Khan,Jan Storek","doi":"10.3899/jrheum.2025-0987","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0987","url":null,"abstract":"OBJECTIVEAutologous hematopoietic cell transplantation (HCT) is an effective treatment for a subset of systemic sclerosis (SSc) patients. Unfortunately, relapse is a significant problem, with no available tests to predict relapse. We studied whether relapse is associated with pre- or post-HCT serum levels of SSc-related autoantibodies.METHODSThe cohort comprised 38 consecutive evaluable SSc patients who underwent HCT at a single center, who were followed for median 33 months. Sixteen (42%) patients developed relapse at median 14 months post-HCT. Autoantibody levels were determined by immunoassays.RESULTSRegarding pre-HCT autoantibodies, in univariate analyses, the cumulative incidence of relapse (CIR) was lower in anti-RNA polymerase III (ARA) positive than negative patients (Hazard ratio (HR)=0.2, P=.04). Conversely, there was a non-significant trend towards higher CIR in patients with positive anti-Ro52 (HR=2.9, P=.05). The CIR was similar in patients positive and negative for anti-topoisomerase antibody (ATA, i.e., Scl70) or anti-nuclear antibody (ANA). In bivariate analyses that included older age as a risk factor for relapse, pre-HCT ARA was still associated with relapse (HR=0.2, P=.04). This was not the case for Ro52 (HR=2.21, P=.16) Regarding post-HCT autoantibody level trajectory, there was no significant difference between patients with vs without relapse.CONCLUSIONIn conclusion, positive ARA pre-HCT is associated with reduced relapse risk, and post-HCT autoantibodies do not appear to be associated with relapse risk.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147684905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Remission rates and predictors in idiopathic inflammatory myopathy subgroups: Insights from a single-center cohort. 特发性炎性肌病亚组的缓解率和预测因素：来自单中心队列的见解。

The Journal of Rheumatology Pub Date : 2026-04-15 DOI: 10.3899/jrheum.2025-1191

Nantakarn Pongtarakulpanit,Sidra Tahir,Varshapriya Suresh,Vaidehi Kothari,Shiri Keret,Eugenia Gkiaouraki,Siamak Moghadam-Kia,Vladimir M Liarski,Dana P Ascherman,Chester V Oddis,Rohit Aggarwal

{"title":"Remission rates and predictors in idiopathic inflammatory myopathy subgroups: Insights from a single-center cohort.","authors":"Nantakarn Pongtarakulpanit,Sidra Tahir,Varshapriya Suresh,Vaidehi Kothari,Shiri Keret,Eugenia Gkiaouraki,Siamak Moghadam-Kia,Vladimir M Liarski,Dana P Ascherman,Chester V Oddis,Rohit Aggarwal","doi":"10.3899/jrheum.2025-1191","DOIUrl":"https://doi.org/10.3899/jrheum.2025-1191","url":null,"abstract":"OBJECTIVEWe evaluated remission rates and predictors across idiopathic inflammatory myopathy (IIM) subgroups using data from a prospective registry.METHODSAdult IIM patients with ≥ 1 year of disease duration, enrolled between 2000 and 2019, were analyzed. Subgroups included dermatomyositis (DM), antisynthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM). Remission was defined as the absence of disease activity by expert assessment. Drug-free remission (DFR) and International Myositis Assessment and Clinical Studies Group (IMACS) remission (≥ 6 months of DFR) were also evaluated. Cumulative incidence of remission and flare was estimated using the Cumulative Incidence Function. Remission predictors were evaluated using cause-specific Cox proportional hazards models. The association between remission and mortality was assessed using Cox models with remission treated as a time-dependent covariate.RESULTSThe cohort (n = 393) was 67.2% female with a mean age of 50.1 years. At 10 years, cumulative probabilities of remission, DFR, and IMACS remission were 40.3%, 23.3%, and 18.1%, respectively. Remission rates were highest in DM (47.4%) and lowest in ASyS (30.1%). Median time to first remission was 3.7 years. The 10-year cumulative incidence of flare following remission was 40.6%. Anti-Mi-2 antibody predicted a higher likelihood of remission (HR 2.08, p = 0.020). Remission and DFR were associated with improved survival.CONCLUSIONRemission rates differed across IIM subgroups, being highest in DM and lowest in ASyS. Anti-Mi-2 antibody was associated with a higher likelihood of remission.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147684908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic literature review informing PReS/CARRA-endorsed recommendations for the treat-to-target strategy in juvenile dermatomyositis. 系统的文献综述告知PReS/ carra认可的针对青少年皮肌炎治疗目标策略的建议。

The Journal of Rheumatology Pub Date : 2026-04-15 DOI: 10.3899/jrheum.2025-1157

Ana Isabel Rebollo-Giménez,Talia Baird,Brian M Feldman,Claas Hinze,Liza J McCann,Ann M Reed,Lisa G Rider,Jessie Cunningham,Alessandro Consolaro,Angelo Ravelli,Jayne Monica MacMahon,Silvia Rosina

{"title":"Systematic literature review informing PReS/CARRA-endorsed recommendations for the treat-to-target strategy in juvenile dermatomyositis.","authors":"Ana Isabel Rebollo-Giménez,Talia Baird,Brian M Feldman,Claas Hinze,Liza J McCann,Ann M Reed,Lisa G Rider,Jessie Cunningham,Alessandro Consolaro,Angelo Ravelli,Jayne Monica MacMahon,Silvia Rosina","doi":"10.3899/jrheum.2025-1157","DOIUrl":"https://doi.org/10.3899/jrheum.2025-1157","url":null,"abstract":"OBJECTIVETo seek for the current evidence in support of the adoption of the treat-to-target (T2T) strategy in the management of juvenile dermatomyositis (JDM).METHODSA systematic literature review (SLR) was performed to address 14 research questions formulated by the Steering Committee (SC) of the project. MEDLINE, Embase, Cochrane Central, and Web of Science databases were searched for clinical trials, observational studies (retrospective and prospective), case reports of > 2 patients, expert recommendations, and systematic reviews published until March 2023. The protocol for the SLR was registered in PROSPERO (CRD42023421254). Quality assessment was performed according to a modified GRADE approach.RESULTSA total of 2,714 articles were retrieved from the databases, with an additional 47 identified through citation searching, and 23 flagged by SC members. Of these, 220 were included in the final review. Evidence was strong or moderate for 2 and 22 articles, respectively, and weak for the remaining articles. Although no published study that compared conventional management with a targeted approach was retrieved, useful insights into specific therapeutic endpoints and optimal timing for their achievement that could be considered in designing the T2T strategy for JDM were obtained.CONCLUSIONThis SLR provides a comprehensive overview of the current knowledge that served as the basis for the consensus definition of the overarching principles and recommendations for treating JDM to target.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147684907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of Spondyloarthritis in Alaska Native and American Indian peoples of Alaska. 阿拉斯加原住民和美洲印第安人脊椎关节炎的患病率。

The Journal of Rheumatology Pub Date : 2026-04-15 DOI: 10.3899/jrheum.2025-1105

Tessalyn Morrison,Peter Holck,Tammy L Choromanski,Amy Wilson,Flora Lee,Elizabeth D Ferucci

{"title":"Prevalence of Spondyloarthritis in Alaska Native and American Indian peoples of Alaska.","authors":"Tessalyn Morrison,Peter Holck,Tammy L Choromanski,Amy Wilson,Flora Lee,Elizabeth D Ferucci","doi":"10.3899/jrheum.2025-1105","DOIUrl":"https://doi.org/10.3899/jrheum.2025-1105","url":null,"abstract":"OBJECTIVEThe objective of this study was to determine the prevalence and clinical characteristics of spondyloarthritis in Alaska Native and American Indian (AN/AI) peoples of Alaska.METHODSWe queried electronic health records from participating tribal health organizations within the Alaska Tribal Health System from 2012 to 2019 to identify adults with a potential diagnosis of spondyloarthritis based on ICD-9 or ICD-10 codes. Medical records were abstracted to confirm the diagnosis and clinical characteristics. Adults who were alive at the end of the study period and had a confirmed clinician diagnosis of spondyloarthritis were included in prevalence calculations. We determined whether included adults had medical record documentation of meeting spondyloarthritis classification criteria.RESULTSThe age-adjusted prevalence of any form of spondyloarthritis was 355 per 100,000 adults (95% confidence interval (CI) 317-397); for psoriatic arthritis it was 162 (95% CI 137-191) and for ankylosing spondylitis it was 107 (95% CI 86-131). Two-thirds (67.0%) of adults with any form of spondyloarthritis who were tested were HLA B27 positive. Two-thirds of adults with spondyloarthritis other than psoriatic arthritis (69.1%) had documentation in their medical record to confirm that they met clinical classification criteria for axial spondyloarthritis.CONCLUSIONThe prevalence of spondyloarthritis in AN/AI peoples of Alaska is lower than previously reported in this population but higher than most populations previously studied Understanding the increased prevalence of spondyloarthritis in this population may help clinicians identify and treat the condition in AN/AI peoples.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147684909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of anti-neutrophil cytoplasmic antibody-associated alveolar hemorrhage: A Bayesian reanalysis of the PEXIVAS trial. 抗中性粒细胞细胞质抗体相关肺泡出血的处理：peexivas试验的贝叶斯再分析。

The Journal of Rheumatology Pub Date : 2026-04-15 DOI: 10.3899/jrheum.2025-0796

Omri A Arbiv,Lee Fidler,Sindhu R Johnson,Andrea S Gershon,Kuan Liu

{"title":"Management of anti-neutrophil cytoplasmic antibody-associated alveolar hemorrhage: A Bayesian reanalysis of the PEXIVAS trial.","authors":"Omri A Arbiv,Lee Fidler,Sindhu R Johnson,Andrea S Gershon,Kuan Liu","doi":"10.3899/jrheum.2025-0796","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0796","url":null,"abstract":"OBJECTIVEThe PEXIVAS trial evaluated plasma exchange (PLEX) and glucocorticoid dose in antineutrophil-cytoplasmic antibody-associated vasculitis (AAV). We reanalyzed PEXIVAS using Bayesian methods to focus on patients with diffuse alveolar hemorrhage (DAH).METHODSIn the original trial, adults with AAV with kidney injury and/or DAH were randomized to PLEX or no PLEX and reduced- or standard-dose glucocorticoids. We evaluated 1-year survival and severe infection among participants with DAH, no DAH, and severe DAH (oxygen saturation ≤85% on room air or mechanical ventilation) across multiple priors. Secondary outcome included severe infection (leading to hospitalization, intravenous antibiotics, or death). We calculated hazard ratios (HR) for survival and odds ratios (OR) for infection, 95% credible intervals (CrI), and probabilities of survival benefit (HR<1) and infection (OR>1).RESULTSAmong 704 participants (191 with DAH, 61 with severe DAH), using uninformative priors, the probability of improved survival was 93% for participants with DAH receiving PLEX (HR 0.52, 95% CrI 0.21-1.26) and 67% without DAH (HR 0.86, 95% CrI 0.43-1.71). Participants receiving reduced-dose glucocorticoids had 98% probability of improved survival without DAH (HR 0.46, 95% CrI 0.22-0.95) but 12% with severe DAH (HR 2.02, 95% CrI 0.64-6.35). PLEX increased severe infection odds (OR 1.25, 95% CrI 0.92-1.70; 92% probability OR>1), whereas reduced-dose glucocorticoids decreased infection odds (OR 0.85, 95% CrI 0.63- 1.15; 85% probability OR<1). Results were consistent across priors.CONCLUSIONPatients with AAV and DAH may benefit from PLEX. Reduced-dose glucocorticoids improve survival for individuals without DAH, but may be harmful in patients with severe DAH.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"238 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147684906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Palliative Care in Rheumatology: Perspectives of Rheumatologists and Palliative Care Clinicians Across the United States. 风湿病的姑息治疗：美国风湿病学家和姑息治疗临床医生的观点。

The Journal of Rheumatology Pub Date : 2026-04-15 DOI: 10.3899/jrheum.2025-0660

Shannon Herndon,Maya N Faison,Jack Kimball,Amanda M Eudy,Ankoor Shah,Jennifer Rogers,Christopher A Jones,David Leverenz

{"title":"Palliative Care in Rheumatology: Perspectives of Rheumatologists and Palliative Care Clinicians Across the United States.","authors":"Shannon Herndon,Maya N Faison,Jack Kimball,Amanda M Eudy,Ankoor Shah,Jennifer Rogers,Christopher A Jones,David Leverenz","doi":"10.3899/jrheum.2025-0660","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0660","url":null,"abstract":"OBJECTIVEExplore perspectives of rheumatologists and palliative care clinicians on the role of palliative care in rheumatic disease.METHODSWe developed two questionnaires, one for rheumatologists and a second for palliative care clinicians, exploring education about the opposite specialty, frequency of Advance Care Planning (ACP) discussions and referrals, and clinician comfort with palliative care skills in rheumatic disease. Questionnaires were distributed to clinicians across the United States in a variety of clinical practice settings.RESULTS201 rheumatologists and 217 palliative care clinicians completed the questionnaires. Few clinicians had received more than a lecture about the opposite specialty. Most rheumatologists reported never or rarely discussing ACP (71.6%), many had not referred a patient to palliative care in the last year in the outpatient (67.2%) or inpatient (47.5%) setting, and they reported low comfort with many palliative care skills. However, the majority agreed that more of their patients could benefit from palliative care (66.2%). Most palliative care clinicians felt less comfortable providing care for rheumatology patients compared to other patients in their practice (75.6%), but the majority felt they could be helpful across many common referral indications for people with rheumatic disease. Clinicians with more advanced education in the opposite specialty reported higher comfort across palliative care skills.CONCLUSIONThere is a clear gap in cross-disciplinary education and collaboration between rheumatologists and palliative care clinicians with low rates of referral and low rates of clinician-comfort. Nonetheless, clinicians feel collaboration would be beneficial. Further partnership is needed to improve this gap.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"441 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147684911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of the Diagnostic Paradigm for Giant Cell Arteritis: From Histopathology to Multi-Modal Imaging Integration Running title: GCA: Histology to Imaging. 巨细胞动脉炎诊断范式的演变：从组织病理学到多模态成像整合

The Journal of Rheumatology Pub Date : 2026-04-01 DOI: 10.3899/jrheum.2025-1205

Jiajia Song,Haibo Jiang,Xiaoyin Wang,Kailin Gong

{"title":"Evolution of the Diagnostic Paradigm for Giant Cell Arteritis: From Histopathology to Multi-Modal Imaging Integration Running title: GCA: Histology to Imaging.","authors":"Jiajia Song,Haibo Jiang,Xiaoyin Wang,Kailin Gong","doi":"10.3899/jrheum.2025-1205","DOIUrl":"https://doi.org/10.3899/jrheum.2025-1205","url":null,"abstract":"Giant cell arteritis (GCA) is a systemic vasculitis that predominantly affects mediumand large-sized arteries. Delayed diagnosis may result in irreversible blindness or stroke. Temporal artery biopsy (TAB), historically regarded as the diagnostic gold standard, has limited sensitivity (40-70%) due to the segmental distribution of inflammatory lesions and carries risks of procedural complications and diagnostic delay. This systematic review aims to:(1) compare the diagnostic accuracy of non-invasive imaging modalities with TAB;(2) assess the prognostic value of imaging findings; and(3) evaluate the implementation of imaging-first clinical pathways. In accordance with the PRISMA 2020 statement, PubMed and Embase,were searched for high-impact studies (n = 36) addressing diagnostic accuracy, guideline updates, and the effectiveness of the fast-track clinic (FTC) model. Colour Doppler ultrasound (CDUS) demonstrating the \"halo sign\" achieved a pooled sensitivity of 88-93%. Accordingly, the 2022 ACR/EULAR classification criteria assign CDUS findings diagnostic weight equivalent to a positive TAB. High-resolution MRI enables quantitative evaluation of cranial arterial wall thickening and contrast enhancement. 18F-FDG PET/CT is particularly useful for assessing systemic inflammatory burden and identifying large-vessel involvement associated with higher relapse risk, while CT angiography (CTA) delineates structural vascular damage. Implementation of FTC pathways reduces diagnostic latency to 24-72 hours and lowers the risk of permanent visual loss by 60-80%. Non-invasive, multimodal imaging has redefined the diagnostic paradigm of GCA. By enabling accurate diagnosis and risk stratification, it informs personalized management strategies. Future directions should emphasize standardized acquisition protocols and artificial intelligence-assisted analysis to reduce operator dependence and further enhance early detection.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147585706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Janus Kinase Inhibitors in Eosinophilic Granulomatosis With Polyangiitis: An International Case Series. Janus激酶抑制剂治疗嗜酸性肉芽肿伴多血管炎：一个国际病例系列。

The Journal of Rheumatology Pub Date : 2026-04-01 DOI: 10.3899/jrheum.2025-1128

Paul Anthony John Russo,Jean-Paul Makhzoum,Vincent Cottin,Edoardo Conticini,Giacomo Emmi,Samuel Lawrance Whittle

引用次数: 0

From Risk to Action: Predictive Profiling and Contemporary Treatment Context in Rheumatoid Arthritis Mortality. 从风险到行动：类风湿关节炎死亡率的预测分析和当代治疗背景。

The Journal of Rheumatology Pub Date : 2026-04-01 DOI: 10.3899/jrheum.2025-1119

Zhen Wang,Jiasi Zheng,Wu-Kai Ma

引用次数: 0